Home » Stocks » ALNA

Allena Pharmaceuticals, Inc. (ALNA)

Stock Price: $1.00 USD 0.00 (0.00%)
Updated Jul 29, 2021 12:04 PM EDT - Market open
Market Cap 75.11M
Revenue (ttm) n/a
Net Income (ttm) -36.90M
Shares Out 55.02M
EPS (ttm) -0.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $1.00
Previous Close $1.00
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.02
Day's Range 1.00 - 1.04
Day's Volume 4,934,571
52-Week Range 0.75 - 2.78

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Allena Pharmaceuticals Inc (NASDAQ: ALNA) has announced a registered direct offering of 21.3 million shares and warrants to purchase up to 10.7 million shares at $1.311. With gross proceeds of $28 milli...

2 weeks ago - Benzinga

NEWTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

2 weeks ago - GlobeNewsWire

NEWTON, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-cla...

2 weeks ago - GlobeNewsWire

NEWTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-clas...

3 weeks ago - GlobeNewsWire

Webinar Scheduled for Wednesday, June 16th @ 12 pm EDT Webinar Scheduled for Wednesday, June 16th @ 12 pm EDT

1 month ago - GlobeNewsWire

Looking for penny stocks to buy in May 2021? Here's some watchlist inspiration The post Top Penny Stocks For Your May Watchlist?

Other stocks mentioned: AHPI, PLIN, RELI, TRIB
2 months ago - PennyStocks

Allena Pharmaceuticals (ALNA) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

2 months ago - Zacks Investment Research

-- Enrollment ongoing in Phase 3 URIROX-2 clinical trial of reloxaliase; interim analysis expected 2Q or 3Q 2022 -- -- Enrolling healthy volunteers in Phase 1b MAD study of ALLN-346; initial data expect...

2 months ago - GlobeNewsWire

NEWTON, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class...

2 months ago - GlobeNewsWire

NEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

3 months ago - GlobeNewsWire

-- Reloxaliase continues to progress through ongoing pivotal Phase 3 URIROX-2 trial for enteric hyperoxaluria -- -- ALLN-346 poised to enter Phase 1 multiple-ascending dose and Phase 2a trials for hyper...

4 months ago - GlobeNewsWire

NEWTON, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzy...

5 months ago - GlobeNewsWire

Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.

Other stocks mentioned: ALRN, MBIO, MCHX, MDWD, OBSV, RWLK
5 months ago - InvestorPlace

-- Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) -- -- Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) --

5 months ago - GlobeNewsWire

Is (ALNA) Outperforming Other Medical Stocks This Year?

6 months ago - Zacks Investment Research

Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

6 months ago - Zacks Investment Research

NEWTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

6 months ago - GlobeNewsWire

Billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 Asset Management, established a 14.37% stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) and a 7.96% po...

Other stocks mentioned: RGLS
7 months ago - GuruFocus

NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

7 months ago - GlobeNewsWire

NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

7 months ago - GlobeNewsWire

NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

7 months ago - GlobeNewsWire

-- Single-Ascending Doses of ALLN-346 Oral Enzyme Well-Tolerated -- -- Non- A bsorption o f ALLN-346 Demonstrated -- -- Advancing to Phase 1b Multiple - Ascending Dose Study and Phase 2 Proof-of-Concept...

7 months ago - GlobeNewsWire

NEWTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

8 months ago - GlobeNewsWire

-- Presented Data at 53 rd Annual Meeting of the American Society of Nephrology (ASN) Highlighting Consistent Treatment Effects Across Phase 2 and 3 Clinical Trials of Reloxaliase in E nteric H yperoxal...

8 months ago - GlobeNewsWire

NEWTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

8 months ago - GlobeNewsWire

Allena Pharmaceuticals, Inc. (ALNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

9 months ago - Zacks Investment Research

NEWTON, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzy...

9 months ago - GlobeNewsWire

-- Extends Allena’s Cash Runway into 4Q 2021 -- -- Debt Can be Converted into Equity at a Price of $4.10 Per Share -- NEWTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASD...

9 months ago - GlobeNewsWire

NEWTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral ...

10 months ago - GlobeNewsWire

-- Expanding URIROX-2 Trial Sites; Interim Analysis on Track for the First Quarter of 2022 –-

11 months ago - GlobeNewsWire

NEWTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e...

11 months ago - GlobeNewsWire

NEWTON, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e...

1 year ago - GlobeNewsWire

NEWTON, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e...

1 year ago - GlobeNewsWire

NEWTON, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e...

1 year ago - GlobeNewsWire

-- Revised URIROX-2 Trial Design to Potentially Reduce Size and Cost of Trial -- -- Finalized Protocol and Selected Contract Research Organization for Phase 1 Clinical Trial of ALLN-346 --

1 year ago - GlobeNewsWire

Allena Pharmaceuticals, Inc. (ALNA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

– Prioritizing Development of Reloxaliase for Patients with Enteric Hyperoxaluria (EH) –

1 year ago - GlobeNewsWire

Allena Pharmaceuticals: Rating This Stock A Buy

1 year ago - Seeking Alpha

Allena Demolished: Weak Phase III And Dismal Prognosis

1 year ago - Seeking Alpha

Phase 3 URIROX-1 Trial Achieves Primary Endpoint with Statistically Significant Reduction in Urinary Oxalate in Patients with Enteric Hyperoxaluria

1 year ago - GlobeNewsWire

Topline data from URIROX-1 expected in 4Q 2019 Topline data from URIROX-1 expected in 4Q 2019

1 year ago - GlobeNewsWire

NEWTON, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral ...

1 year ago - GlobeNewsWire

Allena Pharmaceuticals drug, Reloxaliase, is in Phase 3 clinical trials for enteric hyperoxaluria (EH), a leading cause of the most common type of kidney stone.

1 year ago - Seeking Alpha

NEWTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e...

1 year ago - GlobeNewsWire

Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 years ago - Zacks Investment Research

About ALNA

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients wit... [Read more...]

Industry
Biotechnology
IPO Date
Nov 2, 2017
CEO
Louis Brenner
Employees
45
Stock Exchange
NASDAQ
Ticker Symbol
ALNA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for ALNA stock is "Buy." The 12-month stock price forecast is 7.00, which is an increase of 600.00% from the latest price.

Price Target
$7.00
(600.00% upside)
Analyst Consensus: Buy